Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capecitabine plus paclitaxel with sequential capecitabine alone as the firstline therapy in the treatment of recurrent and late gastric cancer.

Next Previous
Search
Trial Profile

Capecitabine plus paclitaxel with sequential capecitabine alone as the firstline therapy in the treatment of recurrent and late gastric cancer.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 May 2012 Planned end date changed from 1 Dec 2007 to 31 Jul 2009 as reported by Chinese Clinical Trial Register.
    • 13 Apr 2012 Trial phase changed from II to I as reported by Chinese Clinical Trial Register record.
    • 24 Jun 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top